IR Coag Guidelines
UMC Interventional Radiology Standardized Approach for Assessment and Management of Periprocedural Bleeding Risk and Anticoagulant and Antiplatelet Agents
UMC Interventional Radiology Standardized Approach for Assessment and Management of Periprocedural Bleeding Risk and Anticoagulant and Antiplatelet Agents
As of 3/28/20:
Changes below reflect multidisciplinary discussion of the Task Force for Blood Use Protocol Committee. These changes are intended to address peri-procedural transfusion thresholds for platelets and fresh frozen plasma given a projected shortage of available blood products during the COVID-19 pandemic. Changes from the prior iteration of this document (previously updated 11/4/2019) are in red font.
*specified ranges for INR indicate a lower threshold (an ideal for elective procedures) and an upper threshold (to be considered for urgent or emergent cases).
LONG-ACTING DRUGS
LONG-ACTING DRUGS
SHORT-ACTING DRUGS
SHORT-ACTING DRUGS
Antiplatelet Agents
LONG-ACTING ANTIPLATELET DRUGS
LONG-ACTING ANTIPLATELET DRUGS
CHA2DS2 VASc Scoring
CHA2DS2 VASc Scoring
Sum the scores from each category.
Score ≥ 7 = HIGH THROMBOTIC RISK
DUAL-ANTIPLATELET MANAGEMENT
DUAL-ANTIPLATELET MANAGEMENT
